PedAM
Pediatric Disease Annotations & Medicines
| chordoma | ||||
| Disease ID | 362 |
|---|---|
| Disease | chordoma |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:7) HP:0002664 | Neoplasia | 12 HP:0002617 | Aneurysmal dilatation | 1 HP:0011029 | Internal bleeding | 1 HP:0002797 | Increased bone resorption | 1 HP:0012318 | Occipital neuralgia | 1 HP:0002385 | Paraparesis | 1 HP:0030746 | Intraventricular hemorrhage | 1 |
| Disease ID | 362 |
|---|---|
| Disease | chordoma |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:10) C2598155 | pain C1608408 | malignant transformation C0751078 | intermittent diplopia C0334463 | malignant fibrous histiocytoma C0262576 | nerve palsy C0158242 | cervical spinal cord compression C0153687 | cutaneous metastasis C0153676 | lung metastasis C0038525 | subarachnoid hemorrhage C0007682 | cns disease |
| Text Mined Symptom | (Waiting for update.) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0008487 | bortezomib | D000069286 | - | chordoma | MESH:D002817 | therapeutic | 24223206 | ||
| C0008487 | vincristine | D014750 | - | chordoma | MESH:D002817 | therapeutic | 4528471 | ||
FDA approved drug and dosage information(Total Drugs:1) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D002817 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D002817 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |